Promising combo for brain metastases in HER2+ breast cancer falls short
NCT ID NCT07166367
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase II trial tested a combination of two drugs, ASLAN001 and capecitabine, in patients with HER2-positive breast cancer that had spread to the brain and continued to grow despite radiation. The study aimed to see if the treatment could shrink brain tumors. However, the trial was terminated early after enrolling only 3 participants, so no firm conclusions can be drawn about its effectiveness or safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASLAN001 (varlitinib) plus capecitabine (Xeloda)
What this could lead to
If it works, this could offer a new treatment option for HER2-positive breast cancer patients whose brain tumors continue to grow after radiation therapy.
What could go wrong
This trial was terminated early with only 3 participants, so results are very limited. It is unclear if the combination is effective or safe for this specific condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Centre Singapore
Singapore, 169610, Singapore